EVH — Evolent Health, Inc

Is EVH overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Health Information Services

Strong Oversold As of October 3, 2026

Evolent Health, Inc (EVH) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Health Information Services) last closed at $3.46. The rating moved from Oversold to Strong Oversold on October 2, 2026.

See all oversold Healthcare stocks →

AI analysis

Evolent Health, Inc (EVH) operates in a durable secular area—population health and value-based-care services—with recurring-revenue potential tied to Medicare Advantage and payer/provider partnerships. Near-term prospects hinge on contract execution, margin management, and liquidity given a risk-averse market backdrop. Industry dynamics (more aggressive MA product design and payer pricing pressure) present both enrollment opportunity and margin risk. Absent clear signs of accelerating contract wins or material balance-sheet improvement, upside is likely to be gradual and contingent on execution; downside remains tied to policy shifts, client concentration, and broader market risk-off sentiment.

Key factors

  • Core business exposure to Medicare Advantage and value-based care creates recurring revenue opportunities as payers and providers pursue cost-management solutions
  • Scale and client relationships in population-health management and care-delivery enable cross-sell of services and potential contract renewals/expansions
  • Macroeconomic and market risk-off sentiment is limiting capital-market support for healthcare IT/outsourcing peers, which can pressure valuation multiples
  • Ongoing industry shifts (Medicare Advantage plan design changes and aggressive $0-premium push) create both enrollment tailwinds and margin pressure for plan partners
  • Operational execution and ability to convert pipeline wins into profitable long-term contracts are key near-term growth drivers
  • Balance-sheet and liquidity positioning will determine runway for investment in growth and cushion against slower-paying clients or contract timing swings

Risks

  • Intensifying Medicare Advantage competition and benefit expansion by large insurers could compress margins for vendors and reduce addressable pricing
  • Regulatory and policy risks (drug-price negotiation, Medicare rules) that affect payer economics and budget priorities may indirectly reduce outsourcing spend
  • Revenue concentration or dependence on a limited number of large clients or contract renewals could produce sharp top-line volatility if contracts are delayed or terminated
  • Execution risk around integrating offerings, delivering measurable value to clients, and sustaining margins amid price competition
  • Liquidity and capital-market access risk in a risk-off environment that could raise financing costs or limit strategic M&A options
  • Macroeconomic/geopolitical-driven risk aversion may depress near-term valuation multiples irrespective of company fundamentals

See today's live rating, score and targets

Members see the live hourly rating for EVH — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.